Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for NMAD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 23.91M
March 31, 2026 7.945M
December 31, 2025 9.664M
September 30, 2025 4.912M
June 30, 2025 0.6515M
March 31, 2025 1.159M
December 31, 2024 0.8272M
September 30, 2024 1.367M
June 30, 2024 2.246M
March 31, 2024 3.126M
December 31, 2023 3.995M
September 30, 2023 4.923M
June 30, 2023 2.692M
March 31, 2023 4.081M
December 31, 2022 5.165M
September 30, 2022 6.411M
June 30, 2022 7.492M
March 31, 2022 3.473M
December 31, 2021 4.790M
September 30, 2021 6.075M
June 30, 2021 6.866M
March 31, 2021 7.648M
December 31, 2020 5.012M
September 30, 2020 1.141M
June 30, 2020 1.678M
Date Value
March 31, 2020 2.051M
December 31, 2019 2.434M
September 30, 2019 2.756M
June 30, 2019 3.396M
March 31, 2019 3.71M
December 31, 2018 4.126M
September 30, 2018 -0.0141M
June 30, 2018 0.2445M
March 31, 2018 0.6159M
December 31, 2017 0.995M
September 30, 2017 1.395M
June 30, 2017 1.823M
March 31, 2017 0.6661M
December 31, 2016 0.2148M
September 30, 2016 0.738M
June 30, 2016 1.239M
March 31, 2016 1.615M
December 31, 2015 0.3123M
September 30, 2015 0.8049M
June 30, 2015 1.327M
March 31, 2015 1.428M
December 31, 2014 0.2659M
September 30, 2014 0.5939M
June 30, 2014 0.975M
March 31, 2014 -0.0963M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics